INS and cancer: Type II DM population studies demonstrate that patients who use only metformin for management of their DM have a lower cancer risk (1.08, CI=0.96–1.21) compared with those treated with metformin plus a sulphonylurea (1.36, 95% CI=1.19–1.54), vs those on insulin-based regimes (1.42, 95% CI=1.27–1.60; Currie et al, 2009).